The Shire PLC (SHPG) Given Outperform Rating at Royal Bank Of Canada

The Shire PLC (SHPG) Given Outperform Rating at Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of Shire PLC (NASDAQ:SHPG) in a report published on Wednesday morning, MarketBeat.com reports. Royal Bank Of Canada currently has a $213.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently issued reports on the company. Stifel Nicolaus reiterated a buy rating and set a $245.00 price objective on shares of Shire PLC in a research note on Sunday, October 8th. Cantor Fitzgerald reiterated a buy rating and set a $222.00 price objective on shares of Shire PLC in a research note on Thursday, September 14th. ValuEngine cut Shire PLC from a buy rating to a hold rating in a research note on Friday, September 1st. Evercore ISI assumed coverage on Shire PLC in a research note on Wednesday, August 16th. They set an outperform rating and a $196.00 price objective on the stock. Finally, Barclays PLC cut Shire PLC from an overweight rating to an equal weight rating in a research note on Friday, August 11th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $220.91.

Shire PLC (NASDAQ:SHPG) opened at 154.07 on Wednesday. Shire PLC has a one year low of $139.36 and a one year high of $192.64. The firm has a market cap of $45.89 billion, a P/E ratio of 68.94 and a beta of 1.63. The firm’s 50-day moving average price is $153.80 and its 200 day moving average price is $165.05.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. On average, equities research analysts forecast that Shire PLC will post $14.93 EPS for the current year.

The company also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be issued a $0.1527 dividend. This represents a yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio is 41.07%.

A number of hedge funds and other institutional investors have recently modified their holdings of SHPG. American International Group Inc. grew its holdings in Shire PLC by 1.2% in the 1st quarter. American International Group Inc. now owns 4,607 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 54 shares in the last quarter. Neuberger Berman Group LLC grew its holdings in Shire PLC by 7.9% in the 1st quarter. Neuberger Berman Group LLC now owns 14,944 shares of the biopharmaceutical company’s stock valued at $2,604,000 after buying an additional 1,095 shares in the last quarter. United Services Automobile Association grew its holdings in Shire PLC by 4.1% in the 1st quarter. United Services Automobile Association now owns 16,225 shares of the biopharmaceutical company’s stock valued at $2,827,000 after buying an additional 641 shares in the last quarter. Stephens Inc. AR acquired a new position in Shire PLC in the 1st quarter valued at $179,000. Finally, MARSHALL WACE ASIA Ltd acquired a new position in Shire PLC in the 1st quarter valued at $3,515,000. 19.28% of the stock is currently owned by hedge funds and other institutional investors.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Related posts

Leave a Comment